carbidopa/levodopa / Generic mfg. - LARVOL DELTA

Vinpocetine in Patients With Parkinsonian Disease (clinicaltrials.gov) - P2/3 | N=60 | Recruiting | Sponsor: Tanta University | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Movement Disorders • Parkinson's Disease

Laxxon Medical’s Innovative Levodopa / Carbidopa (LXM.5) Oral Dosage Form Demonstrates Significantly Higher Bioavailability (>380%) Compared to Sinemet, Study Results Published in the Journal Pharmaceutics (Businesswire) - "In the study, a novel screen-printing approach was employed to create advanced oral dosage forms that deliver carbidopa and levodopa, the two primary drugs used in the treatment of Parkinson’s disease in a unique sequential form...Lab and pharmacokinetic (PK) studies compared these new formulations to traditional Sinemet, a commonly used Parkinson’s disease therapy that combines carbidopa and levodopa homogeneously distributed within the tablet. Study results showed that Laxxon’s new formulations successfully released the medications in sequence, but the additional controlling of the release of Levodopa through pH sensitive polymers caused a further increase of the bioavailability (>380%) and an extended AuC."

Preclinical • Parkinson's Disease

High-dose carbidopa achieves sustained levodopa pharmacokinetics and efficacy in Parkinson's disease models. (PubMed, J Pharm Pharmacol) - "High-dose carbidopa co-administration is a promising approach to achieve sustained clinical efficacy of levodopa while mitigating the risk of motor complications."

Journal • PK/PD data • CNS Disorders • Movement Disorders • Parkinson's Disease • COMT

Richardson Syndrome Variant of Progressive Supranuclear Palsy: A Case Report. (PubMed, Cureus) - "Initially, levodopa/benserazide was started at a dose of 500 mg/day and increased up to 1,000 mg/day. Amantadine at a dose of 200 mg/day and levodopa/carbidopa sustained release at a dose of 200/50 mg/day were added to the treatment regimen, but no effective clinical response was observed...This case highlights the subtle prodromal features and progressive course of PSP, emphasizing the importance of early recognition. It also contributes to the literature by illustrating the clinical progression and therapeutic challenges in managing PSP, underscoring the value of a multidisciplinary approach to optimize patient outcomes."

Journal • CNS Disorders • Progressive Supranuclear Palsy

...Biocon Pharma Limited...has received tentative approval from the U.S Food and Drug Administration (U.S. FDA) for its abbreviated new drug application (ANDA) for Carbidopa and Levodopa Extended-Release Capsules, in 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg, and 61.25 mg/245 mg strengths. (Medical Dialogues)

ANDA • Parkinson's Disease

Celecoxib in Parkinson Disease as Adjuvant Therapy (clinicaltrials.gov) - P1/2 | N=80 | Recruiting | Sponsor: Tanta University | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Movement Disorders • Parkinson's Disease

Practices and perceptions around splitting of carbidopa/levodopa tablets: a survey of patients and neurologists. (PubMed, Neurodegener Dis Manag) - "Pill splitting is common but burdensome and imprecise. Further research is needed to evaluate clinical impact."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Parkinsonism following immune checkpoint inhibitor therapy with symptom exacerbation during tyrosine kinase inhibitor treatment: a case report (SNO 2025) - "At his next visit, he showed resolution of resting tremor and only mild left upper extremity rigidity. This case raises the question of whether pembrolizumab directly induced parkinsonism or unmasked subclinical PD in a melanoma patient... This case underscores the importance of recognizing parkinsonism as a rare irAE of ICIs. The reproducible symptom fluctuations during TKI therapy warrant further investigation into the potential neuropharmacological effects of cabozantinib."

Case report • Checkpoint inhibition • Clinical • CNS Disorders • Melanoma • Movement Disorders • Oncology • Parkinson's Disease • Solid Tumor • Thyroid Gland Oncocytic Carcinoma

Modulation of PM20D1 expression by rosiglitazone confers neuroprotection in tramadol-induced Parkinsonian rats. (PubMed, Toxicol Rep) - "Parkinson's disease (PD) is a progressive neurodegenerative disorder with no available disease‑modifying therapy, and tramadol misuse has been increasingly associated with PD‑like neurotoxicity through oxidative stress, mitochondrial dysfunction, and apoptosis. The low-dose RSG plus levodopa-carbidopa combination achieved maximal behavioral recovery and dopamine restoration (1023.0 ± 248.0 pg/mL) compared to the tramadol-only group. These findings provide the first evidence that RSG confers neuroprotection against tramadol-induced Parkinsonism through PPARγ-mediated modulation of PM20D1 gene expression, highlighting a novel translational therapeutic axis with potential disease-modifying implications for PD."

IO biomarker • Journal • Preclinical • CNS Disorders • Metabolic Disorders • Movement Disorders • Parkinson's Disease • BCL2 • CASP3 • CASP9

Foslevodopa/Foscarbidopa in Younger Patients Earlier Within Advanced Parkinson's Disease: Post Hoc Analysis of a Randomized Trial. (PubMed, Neurol Ther) - P3 | "LDp/CDp was associated with significantly greater improvements in motor function and sleep vs orally administered levodopa/carbidopa in younger patients earlier within aPD whose symptoms were inadequately controlled by oral/transdermal therapies. Larger real-world studies are needed to confirm findings."

Journal • Retrospective data • CNS Disorders • Movement Disorders • Parkinson's Disease

Parkinsonism following immune checkpoint inhibitor therapy with symptom exacerbation during tyrosine kinase inhibitor treatment: a case report (WFNOS 2025) - "At his next visit, he showed resolution of resting tremor and only mild left upper extremity rigidity. This case raises the question of whether pembrolizumab directly induced parkinsonism or unmasked subclinical PD in a melanoma patient... This case underscores the importance of recognizing parkinsonism as a rare irAE of ICIs. The reproducible symptom fluctuations during TKI therapy warrant further investigation into the potential neuropharmacological effects of cabozantinib."

Case report • Checkpoint inhibition • Clinical • CNS Disorders • Melanoma • Movement Disorders • Parkinson's Disease • Solid Tumor • Thyroid Gland Oncocytic Carcinoma

Celecoxib in Parkinson Disease as Adjuvant Therapy (clinicaltrials.gov) - P1/2 | N=80 | Not yet recruiting | Sponsor: Tanta University

New P1/2 trial • CNS Disorders • Movement Disorders • Parkinson's Disease

Voltammetric analysis of entacapone, levodopa, and carbidopa in tablets: A chemometric approach. (PubMed, J Pharm Biomed Anal) - "The objective of the present work is to develop a voltammetric method for the determination of entacapone (ENT) in the presence of levodopa (LEV) and carbidopa (CAR) in synthetic mixtures and pharmaceutical formulations, using a multivariate approach. To evaluate the validity of the recommended method, a commercial pharmaceutical tablet (Stalevo ® 200 mg) was analyzed. RBF model has the ability to overcome difficulties such as non-linearity and overlaps in the voltammograms."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease • COMT

Metformin in Parkinson Disease (clinicaltrials.gov) - P2/3 | N=60 | Recruiting | Sponsor: Tanta University | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Movement Disorders • Parkinson's Disease

Metformin in Parkinson Disease (clinicaltrials.gov) - P2/3 | N=60 | Not yet recruiting | Sponsor: Tanta University

New P2/3 trial • CNS Disorders • Movement Disorders • Parkinson's Disease

REPLY: Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson's Disease: Extended Real World Data With Outpatient Dose Titration. (PubMed, Mov Disord Clin Pract) - No abstract available

Journal • Real-world evidence • CNS Disorders • Movement Disorders • Parkinson's Disease

Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson's Disease: Extended Real World Data with Outpatient Dose Titration. (PubMed, Mov Disord Clin Pract) - No abstract available

Journal • Real-world evidence • CNS Disorders • Movement Disorders • Parkinson's Disease

Impact of device-aided therapies on quality of life in patients with Parkinson's disease. A comparative multicenter observational study. (PubMed, J Neural Transm (Vienna)) - "No differences in the change of the PDQ-39 total score were detected between both subcutaneous therapies (i.e., foslevodopa/foscarbidopa [fLD/fCD] and continuous subcutaneous apomorphine infusion [CSAI]; p = 0.666) and between subcutaneous and enteral therapies (p = 0.721). Off time, dyskinesia, motor symptoms, and non-motor symptoms improved significantly in the entire cohort. HRQoL improved in PwP after being treated with a DAT."

HEOR • Journal • Observational data • CNS Disorders • Movement Disorders • Parkinson's Disease

Vinpocetine in Patients With Parkinsonian Disease (clinicaltrials.gov) - P2/3 | N=60 | Not yet recruiting | Sponsor: Tanta University

New P2/3 trial • CNS Disorders • Movement Disorders • Parkinson's Disease

The Importance of Medication Reconciliation in a Patient with Parkinson's Disease. (PubMed, Sr Care Pharm) - "His carbidopa/levodopa dose was titrated back to the previous regimen, metoclopramide was discontinued, and his symptoms significantly improved. This case highlights the importance of best practices in medication reconciliation for patients with Parkinson's disease, the impact of drug-disease interactions, and emphasizes the critical role of ambulatory care pharmacists in geriatric patient care."

Journal • CNS Disorders • Geriatric Disorders • Infectious Disease • Movement Disorders • Parkinson's Disease • Pneumonia • Respiratory Diseases

Dopamine Dysregulation Syndrome in Parkinson's Disease. (PubMed, Sr Care Pharm) - "This case describes a patient with PD who presents with DDS following co-administration of self-directed Mucuna pruriens alongside extended-release (ER) and immediate-release (IR) carbidopa/levodopa. Recognizing the presentation and risk factors of DDS is crucial, as is educating and monitoring patients with PD to prevent misuse of both their prescribed dopamine replacement therapy and Mucuna pruriens supplements."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Letter to the Editor on "Cognitive and Psychiatric Adverse Effects of Foslevodopa/Foscarbidopa in Patients with Parkinson's Disease". (PubMed, Mov Disord Clin Pract) - No abstract available

Adverse events • Journal • CNS Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

Dopamine's role in modulating exploratory activity in Drosophila melanogaster (Neuroscience 2025) - "Pharmacologically increasing brain dopamine levels via Levodopa and Carbidopa administration suppressed exploration in wild-type flies...This suggests that the stress-induced suppression of exploration is partially mediated by dopamine signaling through Dop1R1. Together, these findings suggest a complex, receptor-specific modulation of novelty-driven exploration in Drosophila, shaped by both intrinsic dopaminergic signaling and extrinsic stress factors."

CNS Disorders

Dual Approaches for Parkinson's Disease: Role of the Dopaminergic and Non-Dopaminergic Therapies. (PubMed, Curr Aging Sci) - "Non-dopaminergic approaches, such as MAO-B inhibitors, amantadine, anticholinergics, and deep brain stimulation, offer additional symptom control... This review underscores the importance of integrating traditional and emerging therapies for comprehensive PD management. Future research should focus on genetic insights, early detection, and innovative therapeutics to improve patient outcomes and quality of life."

IO biomarker • Journal • CNS Disorders • Gene Therapies • Movement Disorders • Parkinson's Disease

PUCCINI: Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease (clinicaltrials.gov) - P=N/A | N=100 | Not yet recruiting | Sponsor: AbbVie

HEOR • New trial • Real-world evidence • CNS Disorders • Movement Disorders • Parkinson's Disease